Janus Kinase Inhibitors Versus Other Biological Treatments in Alopecia Areata

    March 2016 in “ Scandinavian journal of immunology ”
    Soheil Tavakolpour
    Image of study
    TLDR Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
    The document discussed the complexity of treating alopecia areata (AA) due to the intricate interactions between T cells and hair follicles. Traditional treatments targeting Th1 cells, such as ustekinumab, have not been effective, suggesting that Th1 cells may not be the primary drivers of AA. Recent findings indicated that cytotoxic CD8(+)NKG2D(+) T cells might be responsible for AA, with Janus kinase (JAK) inhibitors showing promise in reversing AA symptoms. Studies on JAK inhibitors like ruxolitinib, tofacitinib, and baricitinib demonstrated their potential effectiveness, although their safety in AA patients remains to be fully established. Additionally, fontolizumab, an anti-IFN-γ, emerged as a potential treatment, warranting further research.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results

    Related Community Posts Join

    6 / 1000+ results

      community Fats on your Head to Stop Hair Loss?

      in Research/Science  142 upvotes 10 months ago
      The conversation discusses the potential of long-chain unsaturated fatty acids, like oleic and linoleic acid, as an additional treatment for hair loss, which may inhibit the enzyme responsible for converting testosterone to DHT and promote hair growth. Users humorously suggest using oils topically and discuss other hair loss treatments, but the main focus is on the science behind fatty acids and their role in hair health.

      community Binding affinity of pyrilutamide!

      in Update  167 upvotes 2 years ago
      Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 1 year ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

    Related Research

    1 / 1 results